Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03809624 · ClinicalTrials.gov registry record · Phase 1
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
A Phase 1 study, sponsored by Inhibrx Biosciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 160
- Enrollment target
NCT03809624 is a Phase 1 study that was terminated before completion, run by Inhibrx Biosciences. The registered enrollment target is 160 participants.
The verdict
NCT03809624, a Phase 1 study, was terminated before completion, sponsored by Inhibrx Biosciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 160 participants
- Enrollment target
Study Summary
This is a first-in-human, open-label, nonrandomized, four-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX-105 and INBRX-105 in combination with Pembrolizumab. INBRX-105, a next generation bispecific antibody, targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor. INBRX-105 provides localized conditional T-cell co-stimulation through 4-1BB agonism.
Interventions
- DRUG Pembrolizumab
- DRUG INBRX-105 - PDL1x41BB antibody
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2019-01-30 |
| Est. Completion | 2024-10-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03809624
The ClinicalTrials.gov registry entry for NCT03809624 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inhibrx Biosciences, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03809624 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03809624 about?
NCT03809624 is a clinical study titled "Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer". This is a first-in-human, open-label, nonrandomized, four-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX-105 and INBRX-105 in combination with Pembrolizumab. INBRX-105, a next generation bispecific antibody, ta...
What is the current status of trial NCT03809624?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 160 participants. The study started on 2019-01-30. Estimated completion is 2024-10-03.
What interventions are being tested in trial NCT03809624?
The interventions under investigation include: Pembrolizumab (DRUG), INBRX-105 - PDL1x41BB antibody (DRUG).
Who is sponsoring clinical trial NCT03809624?
This trial is sponsored by Inhibrx Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.